The relationship between value and price in the free-pricing period and post-assessment price in Germany, a case study in rheumatoid arthritis

03 December 2022

Background

• As a result of the introduction of the AMNOG (Arzneimittelmarkt-Neuordnungsgesetz) law, the German healthcare system allows free-pricing of drugs within the first 12 months of launch.

• During this period, the G-BA (Gemeinsamer Bundesausschuss) evaluate a drug’s additional benefit versus comparators. The outcome of the assessment guides pricing negotiations for reimbursement, applicable from the 13ᵀᴴ month after launch.

• From 2023, the 12-months free-pricing period will be reduced to 6-months due to recently introduced budget constraining measures in Germany.

Objectives

The aim of this study was to:

Assess the relationship between value and price for the free-pricing and the post-assessment period of products (sarilumab, baricitinib, tofacitinib) within a crowded therapeutic area (rheumatoid arthritis, RA)

Forecast and validate the price of upadacitinib for both pricing periods in Germany

Download the full report:

Download